138 related articles for article (PubMed ID: 11044895)
1. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281.
Cosenza M; Gifford AN; Gatley SJ; Pyatt B; Liu Q; Makriyannis A; Volkow ND
Synapse; 2000 Dec; 38(4):477-82. PubMed ID: 11044895
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand.
Lan R; Gatley J; Lu Q; Fan P; Fernando SR; Volkow ND; Pertwee R; Makriyannis A
AAPS PharmSci; 1999; 1(2):E4. PubMed ID: 11741201
[TBL] [Abstract][Full Text] [Related]
3. Large receptor reserve for cannabinoid actions in the central nervous system.
Gifford AN; Bruneus M; Gatley SJ; Lan R; Makriyannis A; Volkow ND
J Pharmacol Exp Ther; 1999 Feb; 288(2):478-83. PubMed ID: 9918548
[TBL] [Abstract][Full Text] [Related]
4. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
5. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo.
Gatley SJ; Lan R; Volkow ND; Pappas N; King P; Wong CT; Gifford AN; Pyatt B; Dewey SL; Makriyannis A
J Neurochem; 1998 Jan; 70(1):417-23. PubMed ID: 9422389
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.
Dhawan J; Deng H; Gatley SJ; Makriyannis A; Akinfeleye T; Bruneus M; Dimaio AA; Gifford AN
Synapse; 2006 Aug; 60(2):93-101. PubMed ID: 16715483
[TBL] [Abstract][Full Text] [Related]
7. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
8. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
9. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Fattore L; Cossu G; Martellotta CM; Fratta W
Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of SR141716A on G-protein activation in rat brain.
Sim-Selley LJ; Brunk LK; Selley DE
Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid modulation of intestinal propulsion in mice.
Colombo G; Agabio R; Lobina C; Reali R; Gessa GL
Eur J Pharmacol; 1998 Feb; 344(1):67-9. PubMed ID: 9570450
[TBL] [Abstract][Full Text] [Related]
13. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
[TBL] [Abstract][Full Text] [Related]
14. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
Rawls SM; Cabassa J; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
[TBL] [Abstract][Full Text] [Related]
15. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2.
Pandolfo P; Pamplona FA; Prediger RD; Takahashi RN
Eur J Pharmacol; 2007 Jun; 563(1-3):141-8. PubMed ID: 17374533
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the abuse potential of AM281, a new synthetic cannabinoid CB1 receptor antagonist.
Botanas CJ; de la Peña JB; Dela Pena IJ; Tampus R; Kim HJ; Yoon SS; Seo JW; Jeong EJ; Cheong JH
Eur J Pharmacol; 2015 Nov; 766():135-41. PubMed ID: 26450088
[TBL] [Abstract][Full Text] [Related]
17. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
[TBL] [Abstract][Full Text] [Related]
18. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
19. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development.
Yang ZM; Paria BC; Dey SK
Biol Reprod; 1996 Oct; 55(4):756-61. PubMed ID: 8879486
[TBL] [Abstract][Full Text] [Related]
20. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.
Steffens M; Szabo B; Klar M; Rominger A; Zentner J; Feuerstein TJ
Neuroscience; 2003; 120(2):455-65. PubMed ID: 12890515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
